Facebook
Twitter
LinkedIn
WhatsApp

🧠 New treatment for leptomeningeal metastases – hope for advanced-stage cancer patients

🧠 A new treatment for leptomeningeal metastases offers real hope for advanced-stage cancer patients.

A groundbreaking study published in Nature Medicine and presented at ASCO 2025 shows promising clinical results for patients with neurological metastases – primarily from breast and lung cancers.

💊 What is HER3-DXd?

HER3-DXd is an antibody-drug conjugate (ADC) targeting the HER3 receptor, which is often found in advanced cancer tumors.

The drug delivers a chemotherapy agent directly to the cancer cell – in a precise and targeted manner, with minimal damage to healthy tissues.

📈 TUXEDO-3 Study Results:

The study included patients with leptomeningeal disease (LMD), a condition previously considered nearly untreatable.

Highlights of the results:
– 65% of patients survived at least 3 months – a significant outcome for this population.
– Neurological function and quality of life were maintained or even improved.
– Side effects included anemia, nausea, and neutropenia – but no new brain toxicities were observed.

🌍 Why is this important?

CNS metastases are among the most difficult to treat. HER3-DXd offers, for the first time, a new treatment option for leptomeningeal metastases, with reasonable safety and promising efficacy – even in cases once deemed terminal.

🔗 Full study link:
https://www.nature.com/articles/s41591-025-03744-1

🧭 Looking for hope?

At Trial-In Pharma, we specialize in locating and accessing innovative cancer treatments – from around the world, personalized and without geographic limitations.

📩 Contact us for more information.

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics